Novo Nordisk and Eli Lilly will dominate the weight loss drug market, experts say
The effect of the drugs on co-morbidities will also be decisive for competition in the market.
by marketwire
Novo Nordisk and Eli Lilly will in the future dominate the market for weight loss drugs when it comes to the ability to create weight loss, according to experts. Decisive for the competition in the market will also be the effect of the drugs on the complications of obesity and the possibilities of creating individualized treatment, Danish business newspaper Børsen reports.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
